Keywords: PhRMA, Benefit-risk assessment, BRAT framework, UMBRA, CIRS

PhRMA transitions management of BRAT framework to CIRS

Article | 31 January 2012

The Pharmaceutical Research and Manufacturers of America (PhRMA) says it has transferred its Benefit-Risk Action Team (BRAT) framework to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in